Położnictwo
Optymalizacja i utrzymanie hemostazy
Środki antyfibrynolityczne
Effectiveness of tranexamic acid on blood loss in patients undergoing elective cesarean section: randomized clinical trial. (opens new window)
Źródło: J Matern Fetal Neonatal Med 2013;26(17):1705-9.
Indeks: PubMed 23574458
https://www.ncbi.nlm.nih.gov/pubmed/23574458 (opens new window)
Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. (opens new window)
Źródło: Lancet 2018;391(10116):125-32.
Indeks: PubMed 29126600
DOI: 10.1016/S0140-6736(17)32455-8
https://www.ncbi.nlm.nih.gov/pubmed/29126600 (opens new window)
Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. (opens new window)
Źródło: Am J Perinatol 2013;30(5):407-13.
Indeks: PubMed 23023559
DOI: 10.1055/s-0032-1326986
https://www.ncbi.nlm.nih.gov/pubmed/23023559 (opens new window)
Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. (opens new window)
Źródło: Am J Perinatol 2011;28(3):233-40.
Indeks: PubMed 20979013
https://www.ncbi.nlm.nih.gov/pubmed/20979013 (opens new window)
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. (opens new window)
Źródło: Lancet 2017;389(10084):2105-16.
Indeks: PubMed 28456509
DOI: 10.1016/S0140-6736(17)30638-4
https://www.ncbi.nlm.nih.gov/pubmed/28456509 (opens new window)
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. (opens new window)
Źródło: Acta Obstet Gynecol Scand 2016;95(1):28-37.
Indeks: PubMed 26698831
DOI: 10.1111/aogs.12798
https://www.ncbi.nlm.nih.gov/pubmed/26698831 (opens new window)
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. (opens new window)
Źródło: Int J Gynaecol Obstet 2016;133(3):312-5.
Indeks: PubMed 26952346
DOI: 10.1016/j.ijgo.2015.09.032
https://www.ncbi.nlm.nih.gov/pubmed/26952346 (opens new window)
Rekombinowany aktywowany czynnik VII (rFVIIa)
Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004. (opens new window)
Źródło: Obstet Gynecol 2007;110(6):1270-8.
Indeks: PubMed 18055720
DOI: 10.1097/01.AOG.0000288515.48066.99
https://www.ncbi.nlm.nih.gov/pubmed/18055720 (opens new window)
The use of recombinant activated FVII in postpartum hemorrhage. (opens new window)
Źródło: Clin Obstet Gynecol 2010;53(1):219-27.
Indeks: PubMed 20142658
DOI: 10.1097/GRF.0b013e3181cc4378
https://www.ncbi.nlm.nih.gov/pubmed/20142658 (opens new window)
Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study. (opens new window)
Źródło: J Perinat Med 2011;40(1):43-9.
Indeks: PubMed 22017328
DOI: 10.1515/JPM.2011.109
https://www.ncbi.nlm.nih.gov/pubmed/22017328 (opens new window)
Postpartum hemorrhage: when uterotonics and sutures fail. (opens new window)
Źródło: Am J Hematol 2012;87 Suppl 1:S16-22.
Indeks: PubMed 22430921
DOI: 10.1002/ajh.23156
https://www.ncbi.nlm.nih.gov/pubmed/22430921 (opens new window)
Recombinant activated factor VII (rFVIIa/NovoSeven®) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan. (opens new window)
Źródło: Int J Hematol 2012;95(1):57-63.
Indeks: PubMed 22160834
DOI: 10.1007/s12185-011-0974-9
https://www.ncbi.nlm.nih.gov/pubmed/22160834 (opens new window)
Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. (opens new window)
Źródło: J Thromb Haemost 2015;13(4):520-9.
Indeks: PubMed 25594352
DOI: 10.1111/jth.12844
https://www.ncbi.nlm.nih.gov/pubmed/25594352 (opens new window)
Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy. (opens new window)
Źródło: Int J Gynaecol Obstet 2004;87(2):178-9.
Indeks: PubMed 15491576
DOI: 10.1016/j.ijgo.2004.08.007
https://www.ncbi.nlm.nih.gov/pubmed/15491576 (opens new window)
Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. (opens new window)
Źródło: Br J Haematol 2001;114(1):174-6.
Indeks: PubMed 11472364
https://www.ncbi.nlm.nih.gov/pubmed/11472364 (opens new window)
Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage. (opens new window)
Źródło: J Obstet Gynaecol Res 2008;34(4 Pt 2):623-30.
Indeks: PubMed 18840167
https://www.ncbi.nlm.nih.gov/pubmed/18840167 (opens new window)
Recombinant factor VIIa as last-resort treatment of desperate haemorrhage. (opens new window)
Źródło: Acta Anaesthesiol Scand 2012;56(5):636-44.
Indeks: PubMed 22489992
DOI: 10.1111/j.1399-6576.2012.02688.x
https://www.ncbi.nlm.nih.gov/pubmed/22489992 (opens new window)
Factor VIIa in puerperal hemorrhage with disseminated intravascular coagulation. (opens new window)
Źródło: Obstet Gynecol 2006;108(3 Pt 2):757-61.
Indeks: PubMed 17018493
DOI: 10.1097/01.AOG.0000197064.44340.d4
https://www.ncbi.nlm.nih.gov/pubmed/17018493 (opens new window)
Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. (opens new window)
Źródło: Anesth Analg 2009;109(6):1908-15.
Indeks: PubMed 19923520
DOI: 10.1213/ANE.0b013e3181c039e6
https://www.ncbi.nlm.nih.gov/pubmed/19923520 (opens new window)
Recombinant factor VIIa to successfully manage disseminated intravascular coagulation from amniotic fluid embolism. (opens new window)
Źródło: Obstet Gynecol 2007;109(2 Pt2):524-5.
Indeks: PubMed 17267882
DOI: 10.1097/01.AOG.0000235711.11817.8c
https://www.ncbi.nlm.nih.gov/pubmed/17267882 (opens new window)
Koncentraty czynników krzepnięcia
The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage--an observational study. (opens new window)
Źródło: Transfus Med 2012;22(5):344-9.
Indeks: PubMed 22994449
https://www.ncbi.nlm.nih.gov/pubmed/22994449 (opens new window)
The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. (opens new window)
Źródło: Int J Obstet Anesth 2010;19(2):218-23.
Indeks: PubMed 20194010
DOI: 10.1016/j.ijoa.2009.08.004
https://www.ncbi.nlm.nih.gov/pubmed/20194010 (opens new window)
Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. (opens new window)
Źródło: Br J Anaesth 2012;108(6):984-9.
Indeks: PubMed 22490316
DOI: 10.1093/bja/aes096
https://www.ncbi.nlm.nih.gov/pubmed/22490316 (opens new window)
Association between fibrinogen levels and severity of postpartum hemorrhage in singleton vaginal deliveries at a Japanese perinatal center. (opens new window)
Źródło: J Nippon Med Sch 2014;81(2):94-6.
Indeks: PubMed 24805095
https://www.ncbi.nlm.nih.gov/pubmed/24805095 (opens new window)
Desmopresyna
A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. (opens new window)
Źródło: Haemophilia 2012;18(1):25-33.
Indeks: PubMed 21624012
DOI: 10.1111/j.1365-2516.2011.02573.x
https://www.ncbi.nlm.nih.gov/pubmed/21624012 (opens new window)
Środki hemostatyczne o działaniu miejscowym
Tisseel for management of traumatic postpartum haemorrhage. (opens new window)
Źródło: Arch Gynecol Obstet 2009;279(3):437-9.
Indeks: PubMed 18985368
DOI: 10.1007/s00404-008-0824-z
https://www.ncbi.nlm.nih.gov/pubmed/18985368 (opens new window)
Uterine packing with chitosan-covered tamponade to treat postpartum hemorrhage. (opens new window)
Źródło: Am J Obstet Gynecol 2024;230(3S):S1061-65.
Indeks: PubMed 38462249
DOI: 10.1016/j.ajog.2022.11.1297
https://pubmed.ncbi.nlm.nih.gov/38462249/ (opens new window)
Use of FloSeal haemostatic gel in massive obstetric haemorrhage: a case report. (opens new window)
Źródło: BJOG 2008;115(6):793-5.
Indeks: PubMed 18355369
DOI: 10.1111/j.1471-0528.2007.01654.x
https://www.ncbi.nlm.nih.gov/pubmed/18355369 (opens new window)
Topical application of recombinant activated factor VII during cesarean delivery for placenta previa. (opens new window)
Źródło: Am J Obstet Gynecol 2017;216(6):608.e1-5.
Indeks: PubMed 28219621
DOI: 10.1016/j.ajog.2017.02.024
https://www.ncbi.nlm.nih.gov/pubmed/28219621 (opens new window)
Fibrin sealant for management of complicated obstetric lacerations. (opens new window)
Źródło: Obstet Gynecol 2010;115(2 Pt 2):403-4.
Indeks: PubMed 20093858
DOI: 10.1097/AOG.0b013e3181bb1e28
https://www.ncbi.nlm.nih.gov/pubmed/20093858 (opens new window)
Badania różnicujące krwawienie chirurgiczne z krwawieniem z koagulopatii (TEG)
Role of thromboelastography versus coagulation screen as a safety predictor in pre-eclampsia/eclampsia patients undergoing lower-segment caesarean section in regional anaesthesia. (opens new window)
Źródło: J Obstet Gynaecol India 2016;66(Suppl 1):340-6.
Indeks: PubMed 27651627
https://www.ncbi.nlm.nih.gov/pubmed/27651627 (opens new window)
Assessment of coagulation in the obstetric population using ROTEM® thromboelastometry. (opens new window)
Źródło: Int J Obstet Anesth 2011;20(4):293-8.
Indeks: PubMed 21835606
https://www.ncbi.nlm.nih.gov/pubmed/21835606 (opens new window)
Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. (opens new window)
Źródło: Obstet Gynecol Surv 2012;67(7):426-35.
Indeks: PubMed 22926249
DOI: 10.1097/OGX.0b013e3182605861
https://www.ncbi.nlm.nih.gov/pubmed/22926249 (opens new window)
Major obstetric haemorrhage: monitoring with thromboelastography, laboratory analyses or both? (opens new window)
Źródło: Int J Obstet Anesth 2014;23(1):10-7.
Indeks: PubMed 24342222
https://www.ncbi.nlm.nih.gov/pubmed/24342222 (opens new window)
Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. (opens new window)
Źródło: Transfusion 2014;54(5):1389-405.
Indeks: PubMed 24117955
DOI: 10.1111/trf.12431
https://www.ncbi.nlm.nih.gov/pubmed/24117955 (opens new window)
Coagulopathy and placental abruption: changing management with ROTEM-guided fibrinogen concentrate therapy. (opens new window)
Źródło: Int J Obstet Anesth 2015;24(2):174-9.
Indeks: PubMed 25659517
https://www.ncbi.nlm.nih.gov/pubmed/25659517 (opens new window)
Haemostatic monitoring during postpartum haemorrhage and implications for management. (opens new window)
Źródło: Br J Anaesth 2012;109(6):851-63.
Indeks: PubMed 23075633
DOI: 10.1093/bja/aes361
https://www.ncbi.nlm.nih.gov/pubmed/23075633 (opens new window)